Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650
in patients with Behcet's disease ( BD ) with special lesions after the administration of
TA-650 at a dosage of 5 mg/kg in weeks 0, 2, and 6, then every 8 weeks after week 14 up to
week 46.